These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 21473199)

  • 1. Topical tazarotene cream (0.1%) in the treatment of facial acne: an open clinical trial.
    Zakaria AS; Paul HK; Rahman MA; Islam MT; Choudhury AM
    Bangladesh Med Res Counc Bull; 2010 Aug; 36(2):43-6. PubMed ID: 21473199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials.
    Shalita AR; Berson DS; Thiboutot DM; Leyden JJ; Parizadeh D; Sefton J; Walker PS; Gibson JR;
    Clin Ther; 2004 Nov; 26(11):1865-73. PubMed ID: 15639698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males.
    Cook-Bolden FE; Gold MH; Guenin E
    J Drugs Dermatol; 2020 Jan; 19(1):78-85. PubMed ID: 32023013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tazarotene foam, 0.1%, for the treatment of acne.
    Smith JA; Narahari S; Hill D; Feldman SR
    Expert Opin Drug Saf; 2016 Jan; 15(1):99-103. PubMed ID: 26560170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical tazarotene: The BEST (balancing efficacy, speed, and tolerability) in acne trial.
    Shalita A
    Cutis; 2004 Oct; 74(4 Suppl):4-8. PubMed ID: 15543713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
    Feldman SR; Werner CP; Alió Saenz AB
    J Drugs Dermatol; 2013 Apr; 12(4):438-46. PubMed ID: 23652892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris.
    Tanghetti E; Dhawan S; Green L; Del Rosso J; Draelos Z; Leyden J; Shalita A; Glaser DA; Grimes P; Webster G; Barnett P; Le Gall N
    J Drugs Dermatol; 2010 May; 9(5):549-58. PubMed ID: 20480800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of topical tazarotene in the treatment of mild to moderate acne.
    Leyden JJ
    Cutis; 2004 Oct; 74(4 Suppl):9-15. PubMed ID: 15543714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris.
    Tanghetti E; Dhawan S; Green L; Ling M; Downie J; Germain MA; Kasteler JS; Kircik L; Oefelein MG; Draelos Z
    J Drugs Dermatol; 2011 Jul; 10(7):783-92. PubMed ID: 21720661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials.
    Tanghetti EA; Werschler WP; Lain T; Guenin E; Martin G; Pillai R
    J Drugs Dermatol; 2020 Jan; 19(1):70-77. PubMed ID: 31985914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A status report on topical tazarotene in the management of acne vulgaris.
    Del Rosso JQ; Tanghetti E
    J Drugs Dermatol; 2013 Mar; 12(3):s53-8. PubMed ID: 23545935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Tazarotene 0.1% Plus Clindamycin 1% Gel Versus Adapalene 0.1% Plus Clindamycin 1% Gel in Facial Acne Vulgaris: A Randomized, Controlled Clinical Trial.
    Maiti R; Sirka CS; Ashique Rahman MA; Srinivasan A; Parida S; Hota D
    Clin Drug Investig; 2017 Nov; 37(11):1083-1091. PubMed ID: 28913735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris.
    Thiboutot D; Arsonnaud S; Soto P
    J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s3-10. PubMed ID: 18575220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tazarotene 0.1 percent cream plus clindamycin 1 percent gel versus tretinoin 0.025 percent gel plus clindamycin 1 percent gel in the treatment of facial acne vulgaris.
    Tanghetti E; Dhawan S; Torok H; Kircik L
    Dermatol Online J; 2007 Jul; 13(3):1. PubMed ID: 18328195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of tazarotene cream 0.1% after a single dose and after repeat topical applications at clinical or exaggerated application rates in patients with acne vulgaris or photodamaged skin.
    Yu Z; Sefton J; Lew-Kaya D; Walker P; Yu D; Tang-Liu DD
    Clin Pharmacokinet; 2003; 42(10):921-9. PubMed ID: 12885265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of topical tazarotene: a review.
    Talpur R; Cox K; Duvic M
    Expert Opin Drug Metab Toxicol; 2009 Feb; 5(2):195-210. PubMed ID: 20213916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris.
    Tanghetti EA; Kircik LH; Green LJ; Guenin E; Harris S; Martin G; Pillai R
    J Drugs Dermatol; 2019 Jun; 18(6):542. PubMed ID: 31251546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial.
    Leyden JJ; Tanghetti EA; Miller B; Ung M; Berson D; Lee J
    Cutis; 2002 Feb; 69(2 Suppl):12-9. PubMed ID: 12095064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris.
    Webster GF; Guenther L; Poulin YP; Solomon BA; Loven K; Lee J
    Cutis; 2002 Feb; 69(2 Suppl):4-11. PubMed ID: 12095066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris.
    Pariser D; Colón LE; Johnson LA; Gottschalk RW
    J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s18-23. PubMed ID: 18575222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.